CALVISI, Diego Francesco
 Distribuzione geografica
Continente #
NA - Nord America 10.336
AS - Asia 6.367
SA - Sud America 3.418
EU - Europa 3.304
AF - Africa 240
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 15
Totale 23.708
Nazione #
US - Stati Uniti d'America 10.036
BR - Brasile 3.059
SG - Singapore 2.770
CN - Cina 1.652
UA - Ucraina 966
HK - Hong Kong 579
VN - Vietnam 501
DE - Germania 497
IT - Italia 451
FR - Francia 306
SE - Svezia 296
GB - Regno Unito 192
FI - Finlandia 188
CA - Canada 129
TR - Turchia 114
BD - Bangladesh 110
AR - Argentina 101
IN - India 99
IQ - Iraq 91
MX - Messico 85
EC - Ecuador 63
PK - Pakistan 61
RU - Federazione Russa 59
VE - Venezuela 55
MA - Marocco 54
ZA - Sudafrica 53
BE - Belgio 52
ES - Italia 51
JP - Giappone 48
UZ - Uzbekistan 47
CZ - Repubblica Ceca 45
ID - Indonesia 45
CO - Colombia 44
AT - Austria 43
PL - Polonia 42
DZ - Algeria 36
PY - Paraguay 29
AU - Australia 26
NL - Olanda 24
NP - Nepal 23
SA - Arabia Saudita 23
CL - Cile 21
JO - Giordania 21
KR - Corea 21
AE - Emirati Arabi Uniti 20
TN - Tunisia 20
AZ - Azerbaigian 19
KE - Kenya 19
EG - Egitto 18
RO - Romania 18
UY - Uruguay 16
IR - Iran 15
JM - Giamaica 14
BO - Bolivia 13
DO - Repubblica Dominicana 13
IL - Israele 13
LT - Lituania 13
PE - Perù 13
CR - Costa Rica 12
PH - Filippine 12
PA - Panama 11
BG - Bulgaria 10
EU - Europa 10
GE - Georgia 10
HN - Honduras 10
OM - Oman 10
SN - Senegal 10
NG - Nigeria 8
NI - Nicaragua 7
PS - Palestinian Territory 7
SY - Repubblica araba siriana 7
BY - Bielorussia 6
KG - Kirghizistan 6
KZ - Kazakistan 6
LB - Libano 6
MY - Malesia 6
RS - Serbia 6
SV - El Salvador 6
TT - Trinidad e Tobago 6
AL - Albania 5
BH - Bahrain 5
CH - Svizzera 5
PT - Portogallo 5
BN - Brunei Darussalam 4
CI - Costa d'Avorio 4
HU - Ungheria 4
LK - Sri Lanka 4
AM - Armenia 3
BA - Bosnia-Erzegovina 3
DK - Danimarca 3
ET - Etiopia 3
GY - Guiana 3
IE - Irlanda 3
PR - Porto Rico 3
SK - Slovacchia (Repubblica Slovacca) 3
TH - Thailandia 3
XK - ???statistics.table.value.countryCode.XK??? 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BS - Bahamas 2
BW - Botswana 2
Totale 23.676
Città #
Dallas 2.971
Singapore 1.519
Chandler 1.428
San Jose 813
Hong Kong 573
Ashburn 527
Jacksonville 527
Princeton 377
Beijing 361
São Paulo 225
Nanjing 219
Lauterbourg 202
Wilmington 170
Sassari 168
Ann Arbor 162
Ho Chi Minh City 161
Dearborn 148
Santa Clara 138
Shanghai 138
Hanoi 128
Los Angeles 123
New York 118
Rio de Janeiro 114
Boardman 106
Council Bluffs 98
Belo Horizonte 84
Nanchang 78
The Dalles 69
Columbus 61
Brasília 57
Munich 55
Orem 54
Tianjin 54
Woodbridge 54
Shenyang 53
Changsha 51
Brussels 50
Hebei 46
Toronto 46
Tokyo 45
Tashkent 44
Helsinki 43
Nuremberg 43
Campinas 41
Porto Alegre 40
Jinan 38
Montreal 38
Baghdad 37
Ribeirão Preto 37
Warsaw 37
Brno 36
Curitiba 36
San Francisco 36
Jiaxing 35
Buffalo 32
Norwalk 32
Atlanta 31
Chennai 31
Frankfurt am Main 31
Izmir 31
Salvador 31
Andover 29
Falls Church 29
Brooklyn 28
Guarulhos 28
Mountain View 28
Da Nang 27
Houston 27
London 26
Denver 25
Goiânia 25
Guangzhou 25
Mexico City 24
Algiers 23
Campo Grande 23
Hangzhou 23
Boston 22
Guayaquil 22
Ningbo 22
Stockholm 22
Chicago 21
Haiphong 21
Kunming 21
Quito 21
Fortaleza 20
Johannesburg 20
Lahore 20
Rome 20
Betim 19
Zhengzhou 19
Amman 18
Baku 18
Casablanca 18
Joinville 18
Poplar 18
Praia Grande 18
Seoul 18
São Bernardo do Campo 18
Contagem 17
Juiz de Fora 17
Totale 13.989
Nome #
A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis 346
Alterations of methionine metabolism in hepatocarcinogenesis: the emergent role of glycine N-methyltransferase in liver injury 233
5' Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon tetrachloride intoxication 204
Aberrant fucosylation sustains the NOTCH and EGFR/NF-kB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma 202
Underserved populations and bacterial and protozoal sexually transmitted infections: a lost health-care opportunity 198
Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans 192
Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis 187
Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells 187
Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease 183
Activation of β-Catenin and Yap1 in Human Hepatoblastoma and Induction of Hepatocarcinogenesis in Mice. 183
Correlation of c-myc overexpression and amplification with progression of preneoplastic liver lesions to malignancy in the poorly susceptible Wistar rat strain 181
Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade 178
Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans 177
Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF-kappa B and Mat1A genes in the early stages of rat liver carcinogenesis 176
Analysis of loss of heterozygosity in neoplastic nodules induced by diethylnitrosomine in the resistant BFF1 rat strain 176
Activation of Beta-Catenin During Hepatocarcinogenesis in Transgenic Mouse Models: Relationships to Phenotype and Tumor Grade 176
Activation of beta-catenin provides proliferative and invasive advantages in c-myc/TGF-alpha hepatocarcinogenesis promoted by phenobarbital 175
Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumor formation in mice via AKT2/mTORC1 cascade. 174
4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras protooncogenes 174
Altered methionine metabolism and global DNA methylation in liver cancer: Relationship with genomic instability and prognosis 174
An infernal cross-talk between oncogenic β-catenin and c-Met in hepatocellular carcinoma: Evidence from mouse modeling 170
Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma 170
Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells 169
Activation of the canonical Wnt/Beta-catenin pathway confers growth advantages in c-My/E2F1 transgenic mouse model of liver cancer 166
The burden of HIV-Associated neurocognitive disorder (HAND) in post-HAART era: Amultidisciplinary review of the literature 161
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver 160
AKT/mTOR activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis. 159
Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines 159
Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis 158
Experimental models to define the genetic predisposition to liver cancer 158
Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53 157
[11C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice. 156
Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans 154
Role of HSP90,CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer 153
MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes 152
Deregulation of methionine metabolism as determinant of progression and prognosis of hepatocellular carcinoma 151
AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. 151
Mitochondrial toxicity and body shape changes during nucleos(t)ide analogues administration in patients with chronic hepatitis B 150
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice 149
Accomplices in crime: The diabolical liaison between protein tyrosine phosphatase 1B and ras in hepatocellular carcinoma 148
SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis 146
Dual-Specific Phosphatase 1 Ubiquitination in Extracellular Signal-Regulated Kinase-Mediated control of Grawth in Human Hepatocellular Carcinoma 146
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells 145
Implication of Bcl 2 family genes in basal and D amphetamine induced apoptosis in preneoplastic and neoplastic rat liver lesions 143
Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans 142
Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma 142
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models 141
Combined treatment with MEK and mTOR inhibitors is effective in in Vitro and in Vivo models of hepatocellular carcinoma 140
Identification and chromosome mapping of loci predisposing to colorectal cancer that control Wnt/b-catenin pathway and progression of early lesions in the rat 139
Role of transcriptional and postttranscriptional regulation of methionine adenosyltransferases in liver cancer progression. 138
Chromosome mapping of multiple loci affecting the genetic predisposition to rat liver carcinogenesis 137
Hydrodynamic transfection for generation of novel mouse models for liver cancer research. 137
Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma 132
Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice 132
Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development 132
The degradation of cell cycle regulators by SKP2/CKS1 ubiquitin ligase is genetically controlled in rodent liver cancer and contributes to determine the susceptibility to the disease. 130
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC 129
CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype 129
Application of comparative functional genomics to identify best-fit mouse models to study human cancer 129
Deregulation of DNA-dependent protein kinase catalytic subunit contributes to human hepatocarcinogenesis development and has a putative prognostic value 128
Frequent loss of heterozygosity at the Hcr1 (Hepatocarcinogenesis resistance) locus on chromosome 10 in primary hepatocellular carcinomas from LFF1 rat strain 128
Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma 127
Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC 127
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice 127
Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease 125
Identification of genetic loci controlling hepatocarcinogenesis on rat chromosomes 7 and 10 123
SNAI1 promotes the cholangiocellular phenotype, but not epithelial-mesenchymal transition, in a murine hepatocellular carcinoma model 123
The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans 123
Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis. 122
Long-term dehydroepiandrosterone and 16alfa-fluoro-5-androsten-17-one administration enhances DNA synthesis and induces expression of c-fos and c-Ha-ras in a selected population of preneoplastic lesions in liver of diethylnitrosamine-initiated rats 122
Transferrin and transferrin receptor gene expression and iron upteke in hepatocellular carcinoma in the rat 121
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer 120
DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma? 119
Phenotypic reversion of rat neoplastic liver nodules is under genetic control 118
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma 118
Lessons from rare tumors: Hepatic lymphoepithelioma-like carcinomas 118
A new mission for an old anti-cancer drug: harnessing hepatocyte-specific metabolic pathways against liver tumors 117
Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma 117
Non-functioning gastroenteropancreatic (GEP) tumors: a 111In-Pentetreotide SPECT/CT diagnostic study. 117
Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations 117
p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. 115
Polygenic control of hepatocarcinogenesis in Copenhagen x F344 rats 114
Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade 113
SUMOylation regulates LKB1 localization and its oncogenic activity in liver cancer 113
Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide 112
NORE1A Tumor Suppressor Candidate Modulates p21CIP1 via p53 110
Epigenetics of liver cancer progression: Role of transcriptional and post-transcriptional regulation of methionine adenosyltransferases in liver cancer progression. 110
The dark side of the moon: AKT as a tumor suppressor in the liver? 108
Sulfatase 1: A new Jekyll and Hyde in hepatocellular carcinoma? 108
Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype 108
The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis 107
Comparison of liver oncogenic potential among human RAS isoforms 107
The warburg effect 97 years after its discovery 107
Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma 107
Programmed death ligand 1 expression in hepatocellular carcinoma: A prognostic marker and therapeutic target for liver cancer? 106
Loss of Fbxw7 synergizes with activated AKT signaling to promote c-Myc dependent cholangiocarcinogenesis 106
Hepatocarcinogenesis following pancreatic islet transplantation in streptozotocin- and autoimmune-diabetic rats 106
Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma. 105
Beta catenin or genomic instability define two categories of liver cancer in transgenic mice 105
Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma 105
Totale 14.365
Categoria #
all - tutte 102.801
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 102.801


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.077 125 9 6 10 23 36 53 65 110 55 122 463
2022/20232.421 255 222 143 409 195 384 3 248 376 10 94 82
2023/2024557 116 37 16 25 103 25 3 57 0 12 48 115
2024/20256.457 43 52 366 170 314 223 546 1.131 2.275 868 295 174
2025/20269.494 426 2.069 1.569 1.111 922 512 1.249 367 448 476 245 100
2026/2027121 121 0 0 0 0 0 0 0 0 0 0 0
Totale 23.964